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ABSTRACT 
Background: Bone destruction in patients with chronic suppurative otitis media (CSOM) and 
cholesteatoma is considered to be quite high. Bone destruction is caused by various 
inflammatory cytokines and osteoclasts including IL-1α and TNF-α. The imbalance between the 
resorption process by osteoclasts and the process of bone formation is also a causative factor for 
bone destruction.  On top of that, the large number of patients is not supported by an equal 
amount of medical facilities and personnel to conduct operative procedures.  
Objective: To analyze the associated of IL-1α level and TNF-α expression on the severity of 
bone destruction in CSOM and cholesteatoma patients. 
Method: The total number of the subjects was 46 patients which group I (TNF-α) consisted of 
26 individuals and group II (IL-1α) contained 26 individuals as well. The analysis was conducted 
in 2 different places (Solo, Indonesia and Surabaya, Indonesia). IL-1α expression was assessed 
by using ELISA kit at the absorbance rate of 450 nm whereas the rabbit anti-TNF-α polyclonal 
antibody was applied to examine TNF-α. The assessment of bone destruction was carried out 
during the operative procedure in Dr. Soetomo General Hospital Surabaya, Indonesia. 
Result: Group I assessment resulted in severe bone destruction of 65.39% whilst group II 
showed severe bone destruction of 65.00%. This study revealed that TNF-α was categorized as 
strong positive (34.62%), moderate positive (42.30%), weak positive (19.23%), and negative 
(3.85%) with the value of r=0.775; p≤0.001. On the other hand, the rate of IL-1α was attained as 
follows: 14.93±4.36 pg/ml, 22.75±12.18 pg/ml, and 31.98±14.16 pg/ml with the value of 
r=0.625; p=0.003. 
Conclusion: There is a significant association between expression of TNF-α and IL-1α level on 
the severity of bone destruction in CSOM and cholesteatoma patients. Hence, it has been proven 
that it is necessary to develop an additional therapeutic interventions to reduce TNF-α and IL-1α 
in CSOM and cholesteatoma patients. 
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INTRODUCTION 1 
Chronic suppurative otitis media (CSOM) and cholesteatoma is one of the main health problems 2 
that can cause morbidity and mortality in the world (1). Complications of CSOM with 3 
cholesteatoma are mainly due to the process of temporal bone destruction. Temporal bone 4 
destruction can cause hearing loss, balance disorders, facial paralysis, periosteal abscess, and 5 
intracranial complications (2). The imbalance between the resorption process and bone formation 6 
occurs in CSOM patients with cholesteatoma. Osteoclasts, which is originated from 7 
monocyte/macrophage hematopoietic cells, plays an important role in bone resorption.  8 
Differentiation and function of osteoclasts are essentialy regulated by the receptor activator of 9 
nuclear factor κβ ligand (RANKL) or receptor activator of nuclear factor κβ (RANK). The 10 
RANKL/RANK bond will activate the osteoclastogenesis cascade (3, 4). 11 
Studies in Poland asserted that levels of tumor necrosis factor alpha (TNF-α), Interleukin 1 12 
αlpha (IL-1α), and Interleukin 6 (IL-6) in cholesteatoma were higher than in granulation tissue 13 
(5). IL-1α increases RANKL expression in osteoblasts and macrophages. Interleukin-1α also 14 
affects fibroblasts and osteoclasts to produce prostaglandin E2 (PGE2) and collagenase which 15 
functions to degrade the matrix of bone (6). The expression of osteoprotegerin (OPG), RANKL, 16 
and TNF-α in cholesteatoma increases compared to the normal skin of the external auditory 17 
meatus (EAM) (7).  18 
Release of TNF-α will induce RANKL, matrix metalloproteinase (MMP), nitric oxide 19 
(NO), and prostaglandin E2 (PG E2) as the factors in bone destruction. MMP protein will induce 20 
osteoclastogenesis, while RANKL stimulates osteoclastogenesis by activating nuclear factor κβ 21 
(NF-κβ). Thus, the number of osteoclasts will consequently increase (8). TNF-α cytokines are 22 
also able to work directly on the bone matrix, in this case, exposing the bone matrix to the 23 
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activity of osteoclasts. The increased NO and PG E2 cause OPG to decrease; hence, the number 1 
of osteoblasts reduces as well. The imbalance between the bone absorption process by 2 
osteoclasts and the process of bone formation by osteoblasts results in destruction of the bone 3 
(7). 4 
The incidence of CSOM in the world ranges approximately from 65-330 million people, in 5 
which 60% (39-200 million) of them found to suffer from severe hearing loss. More than 90% of 6 
patients come from Southeast Asia, the Western Pacific, and Africa. The incidence of CSOM in 7 
Indonesia is estimated to be around 8.36 million people and the prevalence of CSOM in general 8 
is around 3.8% (9). The incidence of CSOM with cholesteatoma in developed countries is 9 
deemed to be low (0.6% to 1.1%), whilst the rate is higher (2.1%) in developing countries (1, 10 
10). A research conducted in Dr. Soetomo General Hospital in 2007-2008 attained 61 cases of 11 
CSOM with cholesteatoma and mastoidectomy surgery was performed (11).  12 
It has been reported that the number of CSOM patients in 2016-2018 treated at dr. 13 
Soetomo General Hospital Surabaya Indonesia was 66 patients with cholesteatoma. Around 90-14 
100% of CSOM patients experience complications of cholesteatoma and require operative 15 
procedure. The capacity of operating room for Otolaryngology - Head and Neck Surgery cases is 16 
for ±200 patients for 1 year. It is estimated that 50 CSOM patients queue every month to be 17 
performed surgery at Dr. Soetomo General Hospital Surabaya, Indonesia. As a result, a long 18 
queue causes 6-month to 1-year of waiting time for the patients to receive further treatment. This 19 
condition requires a solution; therefore, CSOM patients with cholesteatoma are able to obtain 20 
alternative therapy to inhibit mastoid bone destruction. Based on the above description, it is 21 
deemed to be necessary to conduct a research in regards to the correlation of IL-1α level and 22 
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TNF-α expressions with the severity of bone destruction in CSOM patients with cholesteatoma 1 
in Dr. Soetomo General Hospital Surabaya Indonesia. 2 
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METHOD 1 
The subjects of this study were CSOM patients with cholesteatoma who underwent 2 
mastoidectomy surgery at Dr. Soetomo General Hospital Surabaya Indonesia. The subjects were 3 
required to fulfill the inclusion criteria including CSOM patients with cholesteatoma and having 4 
sufficient pathological tissue for IL-1α and TNF-α examination. On the other hand, the exclusion 5 
criteria included a change in diagnosis of CSOM with cholesteatoma to congenital cholesteatoma 6 
or tuberculous otitis media before performing surgery and damage to cholesteatoma tissue which 7 
caused immunohistochemical examination could not be performed. The subjects were divided 8 
into two groups which were Group I for TNF-α examination and Group II performing IL-1α 9 
examination. Prior to the study being conducted, the subjects initially filled the informed 10 
consent.  11 
This study applied analytic observational design conducted within the period of October 12 
2016 to July 2017. This study was carried out in two different cities, namely Surabaya, Indonesia 13 
and Solo, Indonesia. The subject identification process took place in the inpatient room at Dr. 14 
Soetomo General Hospital Surabaya, Indonesia. Furthermore, the pathological tissue of 15 
cholesteatoma, MAE skin, and the severity of bone destruction were collected and assessed in 16 
the Operating Room of Dr. Soetomo General Hospital Surabaya, Indonesia. The IL-1α 17 
assessment was conducted at the Clinical Pathology Laboratory of Dr. Soetomo General 18 
Hospital, Surabaya, Indonesia whereas the immunohistochemical assessment (TNF-α) performed 19 
at the Department of Anatomical Pathology, Faculty of Medicine, Universitas Sebelas Maret, 20 
Solo, Indonesia. By using a cooperative sampling method, the number of samples in the IL-1α 21 
group was obtained in 20 subjects whereas there were 26 subjects in TNF-α group (Figure 1). 22 
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This present study was approved by the Ethical Committee of Dr. Soetomo General Hospital, 1 
Surabaya, Indonesia.  2 
The assessment of bone destruction was performed during the mastoidectomy procedures 3 
based on the damage of bone tissue structure due to cholesteatoma. The severity of bone 4 
destruction was categorized into 3: mild including scutum erosion and ossicular erosion; 5 
moderate including tegmen destruction and entire ossicular destruction; and severe including the 6 
destruction of the entire osicle, labyrinthine bone, facial canal, or KAE posterior wall (5). 7 
The overall IL-1α measurement procedure was conducted in Dr. Soetomo General Hospital 8 
Surabaya, Indonesia. Pathological tissue in the form of cholesteatoma tissue and MAE skin 9 
during surgery were put on plate and stored in a cooler box at 4°C for less than 2 hours. 10 
Afterwards, it was stored at -80°C in the Esco Lexicon II ULT freezer (Esco Technologies Inc., 11 
Hatboro, PA, USA). ELISA examination was executed by using human IL-1α ELISA kit for 12 
lysates (RayBiotech Inc, Georgia, USA). The absorbance value of the material at a wavelength 13 
of 450 nm was interpreted with a Single Humareader (HumaReader, Germany). 14 
TNF-α expression was determined by immunohistochemical staining measured by Rabbit 15 
polyclonal TNF-α antibody (Bioss Antibodies, Woburn, MA, USA) and Olympus BX 51 16 
microscope (Olympus Corporation) with 400x magnification. Each sample was assessed as many 17 
as 9 fields of view. On each field of view, the percentage of strong positive cell, moderate positive 18 
cell, and weak positive cell were calculated to determine the Intensity Distribution Score (IDS).  19 
The IDS formula is as follows: (3 x the percentage of strong positive cell) + (2 x the percentage of 20 
moderate positive cell) + (1 x the percentage of weak positive cell) + (0 x the percentage of 21 
negative cell) (12). Afterwards, the value of IDS was conversed into 4 kinds of TNF-α intensity 22 
level in which it is deemed as strong positive TNF- if IDS is around 276.00-300.00; moderate 23 
 1 
 2 
 3 
 4 
 5 
 6 
 7 
 8 
 9 
10 
11 
12 
13 
14 
15 
16 
17 
18 
19 
20 
21 
22 
23 
24 
25 
26 
27 
28 
29 
30 
31 
32 
33 
34 
35 
36 
37 
38 
39 
40 
41 
42 
43 
44 
45 
46 
47 
48 
49 
50 
51 
52 
53 
54 
55 
56 
57 
58 
59 
60 
61 
62 
63 
64 
65 
positive TNF- if IDS is around 151.00-275.99; weak positive TNF- if IDS is around 76.00-1 
150.99; and negative TNF- if IDS is around 0.00-75.99.   2 
The collected data initially was assessed by using Shapiro-Wilk normality test with 95% 3 
confidence interval (CI). The rate of IL-1α in cholestetoma with MAE skin was compared by 4 
using Mann-Whitney U test and Independent t-test. The analysis of correlation of IL-1α and bone 5 
destruction was executed by using Spearman’s rank correlation test. Similarly, the correlation of 6 
TNF-α and bone destruction was also analysed by using Spearman’s rank correlation (p value < 7 
0.05). The statistical analysis was carried out by applying IBM SPSS Statistics software version 8 
23.0 (IBM Corp., Armonk, NY, USA).  9 
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RESULT 1 
Subject Characteristics  2 
The results of data collection found that most subjects were in the age range of 21-30 years 3 
(38.46%) and followed by the age range of 11-20 years (34.62%) in the TNF-α group. In the IL-4 
1α group, the majority of subjects were between 21-30 years old (45.00%) and followed by the 5 
age of 11-20 years (30.00%). The majority of CSOM patients in the TNF-α group were male 6 
(57.69%) and Javanese (76.92%). Similarly, in the IL-1α group, the majority of the subjects were 7 
male (55.00%) and Javanese (70.00%). The detail of subject characteristics is presented in table 8 
1. 9 
 10 
Bone Destruction 11 
In the TNF-α group, the majority of patients had severe bone destruction of approximately 12 
65.39%.  In the IL-1α group, the majority of patients had a severe bone destruction rate of 13 
65.00%. Whereas, both TNF-α and IL-1α groups had 2 patients with moderate bone destruction 14 
in the moderate category (Table 2). 15 
 16 
TNF-α in Cholesteatoma Tissue 17 
Immunohistochemical examination of TNF-α in 26 subjects revealed several images which can 18 
be seen in figure 2.  Most TNF-α expressions were in the moderate positive category of 42.30% 19 
and followed by a strong positive category of 34.62% (Table 3). 20 
 21 
Measurement of Interleukin-1α Levels 22 
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The mean IL-1α cholesteatoma level was 26.79 ± 13.98 pg/ml with a minimum value of 10.68 1 
pg/ml and a maximum value of 68.45 pg/ml.  Meanwhile, the average IL-1α level on MAE skin 2 
is 4.14 ± 1.56 pg/ml with a minimum value of 2.20 pg/ml and a maximum of 5.81 pg/ml. 3 
Measurement of IL-1α level was performed in 4 CSOM patients. The comparison of mean IL-1α 4 
cholesteatoma levels with mean IL-1α MAE skin had a significant ratio of p ≤ 0.001. The highest 5 
level of IL-1α cholesteatoma was between the ranges of 25.01 - 35.00 pg/ml as much as 35.00% 6 
(table 4). 7 
 8 
Correlation of TNF-α Expression on Bone Destruction 9 
There was a significant correlation between TNF-α expression and the severity of bone 10 
destruction in CSOM patients with cholesteatoma (r = 0.775; p <0.001). There were 9 subjects 11 
who had TNF-α expression in the strong positive category and had a severe bone destruction 12 
(34.62%). TNF-α expression had an even distribution in each category of bone destruction, that 13 
is TNF-α expression in a positive category with 1 subject having mild bone destruction (3.85%), 14 
2 subjects having moderate bone destruction (7.69%), and 8 subjects having severe destruction 15 
bone (30.80%). The correlation of TNF-α expression with the severity of bone destruction can be 16 
seen in table 5. 17 
 18 
Correlation of IL-1α Levels on Bone Destruction 19 
The mean IL-1α levels in bone destruction include mild of 13.87 pg/ml, moderate of 22.75 20 
pg/ml, and severe of 30.85 pg/ml. The mean IL-1α levels in mild, moderate, and severe bone 21 
destruction can be seen in Table 5. Correlation of IL-1α levels with the severity of destruction is 22 
considered as significant (r = 0.625, p = 0.003). 23 
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DISCUSSION 1 
TNF-α plays an important role in causing bone destruction although it uses different techniques 2 
in its examination, different sample characteristics, different ways of calculating the TNF-α 3 
immunoreactivity, and different antibodies. This study has proven that there is a significant 4 
correlation between TNF-α expression and the severity of bone destruction in CSOM patients 5 
with cholesteatoma (5, 13) . The release of TNF-α will induce RANKL, MMP, NO, and PG E2 6 
as factors in bone destruction. MMP protein will induce osteoclastogenesis, while RANKL 7 
stimulates osteoclastogenesis by activating NF-κβ. Consequently, the number of osteoclasts will 8 
increase. Tumor necrosis factor-α is also able to work directly on the bone matrix, exposing the 9 
bone matrix to the activity of osteoclasts. Increasing NO and PG E2 causes OPG to decrease 10 
resulting the number of osteoblasts decreases. The imbalance between the bone absorption 11 
process by osteoclasts and the process of bone formation by osteoblasts results in destruction of 12 
the bone (7, 14, 15). 13 
The comprehension of the bone destruction process that occurs in CSOM with 14 
cholesteatoma at the molecular level is expected to be a molecular basis for the development of 15 
future therapeutic strategies. TNF-α cytokines can be a new target in CSOM therapy. Research 16 
continues to be conducted to find ways to stop the inflammatory process by suppressing TNF-α; 17 
hence, the bone destruction can be inhibited. The use of anti TNF-α or TNF-α systemic 18 
inhibitors such as infliximab and adalimumab has been implemented abroad as therapy in 19 
Chron’s disease (15, 16). Both of these medicines, etanercept and golimumab, are also used to 20 
treat ankylosing spondylitis (17).  21 
Interleukin-1α is not the only cytokine that plays a role in bone resorption in CSOM with 22 
cholesteatoma. TNF-α cytokines also have an important role in the process. Studies in Japan 23 
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provide the fact that there is an increase in TNF-α and IL-1 which is detected in both acquired 1 
cholesteatoma and congenital cholesteatoma compared to MAE normal skin. The RT-PCR 2 
technique shows that messenger ribonucleic acid (mRNA) for IL-1α and TNF-α was detected at 3 
5/5 acquired cholesteatoma, whereas in congenital cholesteatoma strong mRNA expression for 4 
TNF-α was found in 5/5 cases. However, it is deemed to be weak for IL-1α as it occurs only in 5 
4/5 cases. The ELISA technique obtained higher IL-1α levels in acquired cholesteatoma than in 6 
congenital cholesteatoma, whereas TNF-α levels did not differ greatly in these two types of 7 
cholesteatoma (15, 18, 19).  8 
Interleukin-1α is a cytokine that plays a role in inflammation and increases bone 9 
destruction directly or through increased osteoclastogenesis in CSOM with cholesteatoma. 10 
Various studies on IL-1α inhibition have been carried out on various diseases related to bone 11 
resorption, including rheumatoid arthritis, gout, ankylosing spondylitis, and erosive 12 
osteoarthritis. Several IL-1α inhibiting agents include anakinra, rilonacept, and MABp1. 13 
Anakinra has been used as a therapy for rheumatoid arthritis and ankylosing spondylitis (20, 21).   14 
However, research on IL-1α antagonists as the target of therapy in CSOM with 15 
cholesteaoma has never been done. Providing recombinant IL-1RA can be a new target for 16 
adjuvant therapy in addition to surgery on CSOM with cholesteatoma. The aim is to reduce IL-17 
1α activity so that it reduces the inflammatory process and inhibits the growth of cholesteatoma 18 
and bone destruction process. 19 
 20 
CONCLUSION 21 
In this study, there is a strong positive association between IL-1α levels on the severity of bone 22 
destruction in CSOM and cholesteatoma patients. Furthermore, it is attained that there is also a 23 
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strong positive correlation between TNF-α expression and the severity of bone destruction in 1 
CSOM and cholesteatoma patients. 2 
 3 
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Figure 1. Flowchart of Subject Sampling
Figure
Figure 2. The intensity of TNF-α expression in cholesteatoma tissue. A. Strong positive is indicated by the dark 
brown cytoplasm (white arrow). B. Moderate positive (blue arrow). C. Weak positive (yellow arrow). D. Negative 
(red arrow).
TABLE AND LEGEND 1 
Table 1. Subject Characteristics  2 
Characteristics IL-1α (n=20) TNF-α (n=26) 
Age (years) n % n % 
≤ 10 2 10.00 1 3.85 
11 - 20 6 30.00 9 34.62 
21 - 30 9 45.00 10 38.46 
31 - 40 2 10.00 3 11.53 
≥ 41 1 5.00 3 11.53 
Sex     
Male 11 55.00 15 57.69 
Female 9 45.00 11 42.31 
Race     
Javanese 14 70.00 20 76.92 
Maduranese 4 20.00 4 15.38 
Banjarese 2 10.00 2 7.70 
  3 
Table 2. Distribution of the Severity of Bone Destruction 4 
Severity of Bone 
Destruction 
IL-1α (n=20) TNF-α (n=26) 
n % n % 
Mild 5 25.00 7 26.92 
Moderate 2 10.00 2 7.69 
Severe 13 65.00 17 65.39 
 5 
Table 3. Distribution of patients based on TNF-α expression 6 
TNF-α expression N=26 % 
Negative 1 3.85 
Weak Positive 5 19.23 
Moderate Positive 11 42.30 
Strong positive 9 34.62 
 7 
Table 4. IL-1α levels of cholesteatoma 8 
IL-1α (pg/ml) Mean ± SD Min – Max n (%) 
5.00 – 15.00 12.71 ± 1.64 10.68 – 14.14 5 (25.00) 
15.01 – 25.00 20.38 ± 2.79 16.85 – 23.77 5 (25.00) 
25.01 – 35.00 30.76 ± 2.99 26.17 – 33.89 7 (35.00) 
≥ 35.00 51.72 ± 14.99 39.53 – 68.45 3 (15.00) 
 9 
Table 5. Correlation between IL-1α and TNF-α Levels with Severity of Bone Destruction 10 
 IL-1α (n=20) 
r p 
TNF-α (n=26) 
r p 
Mean±SD Min – Man - + ++ +++ 
Table
Mild 14.93±4.36 10.68 – 20.39 
0.625 0.003 
1 5 1 0 
0.775 0.000 
Moder
ate 
22.75±12.18 14.14 – 31.37 0 0 2 0 
Severe 31.98±14.16 13.69 – 68.45 0 0 8 9 
 1 
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Abstract: Background: Bone destruction in patients with chronic suppurative otitis media (CSOM)
and cholesteatoma is considered to be quite high. Bone destruction is caused by
various inflammatory cytokines and osteoclasts including IL-1α and TNF-α. The
imbalance between the resorption process by osteoclasts and the process of bone
formation is also a causative factor for bone destruction. On top of that, the large
number of patients is not supported by an equal amount of medical facilities and
personnel to conduct operative procedures.
Objective: To analyze the associated of IL-1α level and TNF-α expression on the
severity of bone destruction in CSOM and cholesteatoma patients.
Method: The total number of the subjects was 46 patients which group I (TNF-α)
consisted of 26 individuals and group II (IL-1α) contained 26 individuals as well. The
analysis was conducted in 2 different places (Solo, Indonesia and Surabaya,
Indonesia). IL-1α expression was assessed by using ELISA kit at the absorbance rate
of 450 nm whereas the rabbit anti-TNF-α polyclonal antibody was applied to examine
TNF-α. The assessment of bone destruction was carried out during the operative
procedure in Dr. Soetomo General Hospital Surabaya, Indonesia.
Result: Group I assessment resulted in severe bone destruction of 65.39% whilst
group II showed severe bone destruction of 65.00%. This study revealed that TNF-α
was categorized as strong positive (34.62%), moderate positive (42.30%), weak
positive (19.23%), and negative (3.85%) with the value of r=0.775; p≤0.001. On the
other hand, the rate of IL-1α was attained as follows: 14.93±4.36 pg/ml, 22.75±12.18
pg/ml, and 31.98±14.16 pg/ml with the value of r=0.625; p=0.003.
Conclusion: There is a significant association between expression of TNF-α and IL-1α
level on the severity of bone destruction in CSOM and cholesteatoma patients. Hence,
it has been proven that it is necessary to develop an additional therapeutic
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interventions to reduce TNF-α and IL-1α in CSOM and cholesteatoma patients.
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